REGENERATIVE MEDICINE

FROM BENCH TO BEDSIDE




Holostem Terapie Avanzate is the first biotechnological company entirely devoted to development, manufacture, registration and distribution of Advanced Therapies Medicinal Products (ATMPs) based on cultures of epithelial stem cells both for cell and gene therapy.


The main aim of Holostem Terapie Avanzate is to promote epithelial stem cell-based

Regenerative Medicine for patients with no alternative therapeutic solutions.


Holostem Terapie Avanzate is a university spin-off founded in 2008 through the profitable union among the scientific know-how of internationally renowned researchers such as Michele De Luca and Graziella Pellegrini, the innovative spirit of the University of Modena and Reggio Emilia  and the industrial know-how of Chiesi Farmaceutici S.p.A., a leading pharmaceutical company in Italy.


Holostem Terapie Avanzate has a highly experienced management team, with a sound know-how derived from a long tenure both in business administration and in academic research, successfully applied since many years in translational medicine.


Michele De Luca and Graziella Pellegrini are internationally recognized as leading scientists in the field of epithelial stem cell biology aimed at clinical application in Regenerative Medicine and played a pivotal role in epithelial stem cell-mediated cell therapy and gene therapy.


Graziella Pellegrini and Michele De Luca were first in establishing human limbal stem cell culture aimed at corneal regeneration in patients with severe limbal stem cell deficiency due to massive thermic and chemical burn-dependent destruction of the cornea. This treatment led to recovery of vision in hundreds of patients with poor or no alternative therapy. In August 2008, the European Medicines Agency (EMA) designated their limbal stem cell therapy as an Orphan Medicinal Product and in 2015 the European Commission has granted to Holoclar® a conditional marketing authorization.


Michele De Luca and Graziella Pellegrini established in 2006 a proof of principle of the feasibility of ex-vivo gene therapy for laminin 332-dependent Junctional Epidermolysis Bullosa (JEB) by means of transplantation of autologous epidermal sheets prepared from genetically corrected epidemal stem cells.


OUR COMPANY

MANAGEMENT

Holostem Terapie Avanzate has a highly experienced management team, with a sound know-how derived from a long tenure both in business administration and in academic research, successfully applied since many years in translational medicine...

Michele De Luca and Graziella Pellegrini are internationally recognized as leading scientists

in the field of epithelial stem cell biology aimed at clinical application and played a pivotal role in epithelial stem cell-mediated cell therapy

and gene therapy...

(placeholder)
(placeholder)
(placeholder)

STEM CELLS

TECHNOLOGY

GENE THERAPY

(placeholder)

CELL THERAPY

(placeholder)

PUBLICATIONS

Our scientist are author of over 150 peer-reviewed publications in major international journals.


ABOUT US



(placeholder)


MISSION


Provide patients suffering from

severe or rare, untreatable diseases

with stem cell-based advanced therapies

through ethical and scientific excellence

(placeholder)
(placeholder)

SCIENTIFIC BACKGROUND

© 2017  Holostem Terapie Avanzate S.r.l.


VAT: 03213240363 -

Payed Up Capital: Euro 700.000,00

Companies Register Office - Modena: 03213240363

Registered with the Administrative Economic Register: MO-368370

Company subject to the management and coordination of Valline s.r.l.

FOLLOW US ON


Holostem Terapie Avanzate Srl

joins Clust-ER Association

"Life Sciences and Wellbeing"


June 2, 2017

NEWS